These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
375 related articles for article (PubMed ID: 31738823)
41. Primary Bone Lymphoma Exhibits a Favorable Prognosis and Distinct Gene Expression Signatures Resembling Diffuse Large B-Cell Lymphoma Derived From Centrocytes in the Germinal Center. Li X; Xu-Monette ZY; Yi S; Dabaja BS; Manyam GC; Westin J; Fowler N; Miranda RN; Zhang M; Ferry JA; Medeiros LJ; Harris NL; Young KH Am J Surg Pathol; 2017 Oct; 41(10):1309-1321. PubMed ID: 28817403 [TBL] [Abstract][Full Text] [Related]
42. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. Schmitz R; Wright GW; Huang DW; Johnson CA; Phelan JD; Wang JQ; Roulland S; Kasbekar M; Young RM; Shaffer AL; Hodson DJ; Xiao W; Yu X; Yang Y; Zhao H; Xu W; Liu X; Zhou B; Du W; Chan WC; Jaffe ES; Gascoyne RD; Connors JM; Campo E; Lopez-Guillermo A; Rosenwald A; Ott G; Delabie J; Rimsza LM; Tay Kuang Wei K; Zelenetz AD; Leonard JP; Bartlett NL; Tran B; Shetty J; Zhao Y; Soppet DR; Pittaluga S; Wilson WH; Staudt LM N Engl J Med; 2018 Apr; 378(15):1396-1407. PubMed ID: 29641966 [TBL] [Abstract][Full Text] [Related]
43. SOCS1 mutation subtypes predict divergent outcomes in diffuse large B-Cell lymphoma (DLBCL) patients. Schif B; Lennerz JK; Kohler CW; Bentink S; Kreuz M; Melzner I; Ritz O; Trümper L; Loeffler M; Spang R; Möller P Oncotarget; 2013 Jan; 4(1):35-47. PubMed ID: 23296022 [TBL] [Abstract][Full Text] [Related]
44. Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features. Li M; Liu Y; Wang Y; Chen G; Chen Q; Xiao H; Liu F; Qi C; Yu Z; Li X; Fan L; Guo Y; Yan Q; Guo S; Wang Z Am J Surg Pathol; 2017 Oct; 41(10):1322-1332. PubMed ID: 28319526 [TBL] [Abstract][Full Text] [Related]
45. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation. Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190 [TBL] [Abstract][Full Text] [Related]
46. Genomic Profile and Pathologic Features of Diffuse Large B-Cell Lymphoma Subtype of Methotrexate-associated Lymphoproliferative Disorder in Rheumatoid Arthritis Patients. Carreras J; Yukie Kikuti Y; Miyaoka M; Hiraiwa S; Tomita S; Ikoma H; Kondo Y; Shiraiwa S; Ando K; Sato S; Suzuki Y; Miura I; Roncador G; Nakamura N Am J Surg Pathol; 2018 Jul; 42(7):936-950. PubMed ID: 29738359 [TBL] [Abstract][Full Text] [Related]
47. Selective dysregulation of ROCK2 activity promotes aberrant transcriptional networks in ABC diffuse large B-cell lymphoma. Ricker E; Verma A; Marullo R; Gupta S; Ye C; Pannellini T; Manni M; Tam W; Inghirami G; Elemento O; Cerchietti L; Pernis AB Sci Rep; 2020 Aug; 10(1):13094. PubMed ID: 32753663 [TBL] [Abstract][Full Text] [Related]
48. Diagnostic approaches and future directions in Burkitt lymphoma and high-grade B-cell lymphoma. King RL; Hsi ED; Chan WC; Piris MA; Cook JR; Scott DW; Swerdlow SH Virchows Arch; 2023 Jan; 482(1):193-205. PubMed ID: 36057749 [TBL] [Abstract][Full Text] [Related]
49. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Chapuy B; Stewart C; Dunford AJ; Kim J; Kamburov A; Redd RA; Lawrence MS; Roemer MGM; Li AJ; Ziepert M; Staiger AM; Wala JA; Ducar MD; Leshchiner I; Rheinbay E; Taylor-Weiner A; Coughlin CA; Hess JM; Pedamallu CS; Livitz D; Rosebrock D; Rosenberg M; Tracy AA; Horn H; van Hummelen P; Feldman AL; Link BK; Novak AJ; Cerhan JR; Habermann TM; Siebert R; Rosenwald A; Thorner AR; Meyerson ML; Golub TR; Beroukhim R; Wulf GG; Ott G; Rodig SJ; Monti S; Neuberg DS; Loeffler M; Pfreundschuh M; Trümper L; Getz G; Shipp MA Nat Med; 2018 May; 24(5):679-690. PubMed ID: 29713087 [TBL] [Abstract][Full Text] [Related]
50. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Lacy SE; Barrans SL; Beer PA; Painter D; Smith AG; Roman E; Cooke SL; Ruiz C; Glover P; Van Hoppe SJL; Webster N; Campbell PJ; Tooze RM; Patmore R; Burton C; Crouch S; Hodson DJ Blood; 2020 May; 135(20):1759-1771. PubMed ID: 32187361 [TBL] [Abstract][Full Text] [Related]
51. MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma. Takeuchi T; Yamaguchi M; Kobayashi K; Miyazaki K; Tawara I; Imai H; Ono R; Nosaka T; Tanaka K; Katayama N Cancer; 2017 Apr; 123(7):1166-1173. PubMed ID: 27915469 [TBL] [Abstract][Full Text] [Related]
54. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases. Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841 [No Abstract] [Full Text] [Related]
55. Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma. van Imhoff GW; Boerma EJ; van der Holt B; Schuuring E; Verdonck LF; Kluin-Nelemans HC; Kluin PM J Clin Oncol; 2006 Sep; 24(25):4135-42. PubMed ID: 16943530 [TBL] [Abstract][Full Text] [Related]
56. Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma. Klapper W; Kreuz M; Kohler CW; Burkhardt B; Szczepanowski M; Salaverria I; Hummel M; Loeffler M; Pellissery S; Woessmann W; Schwänen C; Trümper L; Wessendorf S; Spang R; Hasenclever D; Siebert R; Blood; 2012 Feb; 119(8):1882-7. PubMed ID: 22238326 [TBL] [Abstract][Full Text] [Related]
57. Characterization of genomic imbalances in diffuse large B-cell lymphoma by detailed SNP-chip analysis. Scholtysik R; Kreuz M; Hummel M; Rosolowski M; Szczepanowski M; Klapper W; Loeffler M; Trümper L; Siebert R; Küppers R; Int J Cancer; 2015 Mar; 136(5):1033-42. PubMed ID: 25042405 [TBL] [Abstract][Full Text] [Related]
58. A super-SILAC based proteomics analysis of diffuse large B-cell lymphoma-NOS patient samples to identify new proteins that discriminate GCB and non-GCB lymphomas. van der Meeren LE; Kluiver J; Rutgers B; Alsagoor Y; Kluin PM; van den Berg A; Visser L PLoS One; 2019; 14(10):e0223260. PubMed ID: 31603917 [TBL] [Abstract][Full Text] [Related]
59. MYC rearrangement and MYC/BCL2 double expression but not cell-of-origin predict prognosis in R-CHOP treated diffuse large B-cell lymphoma. Xu J; Liu JL; Medeiros LJ; Huang W; Khoury JD; McDonnell TJ; Tang G; Schlette E; Yin CC; Bueso-Ramos CE; Lin P; Li S Eur J Haematol; 2020 Apr; 104(4):336-343. PubMed ID: 31944390 [TBL] [Abstract][Full Text] [Related]
60. Homogeneous immunophenotype and paucity of secondary genomic aberrations are distinctive features of endemic but not of sporadic Burkitt's lymphoma and diffuse large B-cell lymphoma with MYC rearrangement. Barth TF; Müller S; Pawlita M; Siebert R; Rother JU; Mechtersheimer G; Kitinya J; Bentz M; Möller P J Pathol; 2004 Aug; 203(4):940-5. PubMed ID: 15258997 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]